What is the purpose of this trial?
This is a multicenter, open-label, single-arm phase 3 trial to assess the efficacy and safety of ATA129 for the treatment of Epstein Barr Virus-associated post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of solid organ transplant (SOT) after failure of rituximab or rituximab plus chemotherapy.
Start Date: 03/12/2018
End Date: 11/30/2020
Last Updated: 06/24/2018
Study HIC#: 2000021894